COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. receives $240,000 grant from FDA for Canalevia-CA1 study on chemotherapy-induced diarrhea in dogs. Focus on CID treatment effectiveness -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health announces submission of abstract detailing preliminary findings from clinical trial on a novel oral liquid formulation of crofelemer for SBS-IF patients, supporting the focus on reducing PS needs in intestinal failure patients -
-
-
COMMUNIQUÉ DE PRESSE
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) receives FDA renewal for Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea (CID) in dogs, with conditional approval extended until December 2026
